Paul Klaverweiden
Psychiatric/Mental Health · Fruitland, MDNPI 1760984454
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (55.3%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. AbbVie accounts for 71.7% of it on its own, with 23 other manufacturers making up the rest. Reporting peaked in 2021 at $5,416 and has fallen 71.6% since, to $1,538 in 2025. Among psychiatric/mental health clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 325 payments — averaging $52.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$12K
- Otsuka America Pharmaceutical, Inc.$510
- Alkermes, Inc.$492
- Neurocrine Biosciences, Inc.$462
- Lundbeck LLC$460
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$451
- plus $2K from 18 others
What the payments were for
- Speaking & faculty fees$9,35055%
- Travel & lodging$1,3758%
- Food & beverage$6,08936%
- Education$921%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$16,906 in reported general payments places this provider in the 95th percentile of 1,461 psychiatric/mental health providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 38 | $58,576 |
| VraylarCariprazine Hcl | 36 | $47,850 |
| NuedextaDextromethorphan Hbr/Quinidine | 20 | $24,174 |
| Paliperidone ErPaliperidone | 109 | $18,101 |
| ZubsolvBuprenorphine Hcl/Naloxone Hcl | 13 | $16,968 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 27 | $7,162 |
| Chlorpromazine Hcl | 30 | $7,001 |
| QuviviqDaridorexant Hcl | 13 | $6,069 |
| Lurasidone Hcl | 28 | $5,513 |
| Aripiprazole | 33 | $5,113 |
| Fluvoxamine Maleate | 136 | $5,071 |
| VyvanseLisdexamfetamine Dimesylate | 11 | $4,156 |
| Divalproex Sodium | 104 | $3,863 |
| Quetiapine Fumarate | 212 | $2,889 |
| Haloperidol | 33 | $2,375 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti | $510 | $58,57638 claims |
| AbbVieVraylar | $12,128 | $47,85036 claims |
| Orexo US, Inc.Zubsolv | $12 | $16,96813 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $130 | $6,06913 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $251 | $4,15611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,461 psychiatric/mental health providers in Maryland.
Other psychiatric/mental health in Fruitland
- Hara OyedejiOwings Mills$780K
- Ilya RozenbergGlen Burnie$572K
- Michelle WilliamsColumbia$158K
- Kristin ClemensGaithersburg$36K
- Antonio HeroldHavre de Grace$23K
- Margaret WebbAberdeen$16K
- Susan KrausTowson$16K
- Anyinke AtabongRockville$15K
- Zenatsehay GebretsadikColumbia$15K
- Travis BairdGlen Burnie$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.